If an HIV prevention pill that provides a month of protection at a time performs well in two ongoing clinical trials, it could become the next big thing in HIV prevention after the lenacapavir injection. A new licensing agreement is paving the way for South Africa’s Aspen Pharmacare to produce the pill should the study…
Funda ngesiZuluBy Palesa Matlala South Africa says African countries must invest more of their own money in HIV programmes as international donor funding continues to decline. A new once a month HIV prevention pill is showing promise, but it is still being tested and cannot yet be used by the public. South Africa has one…
Kampala — For more than two decades, scientific innovation and international financing have worked together to transform HIV from a deadly disease into a manageable chronic condition for millions of people. But today, the two pillars that have sustained the global HIV response appear to be moving in different directions. Researchers are reporting some of…
Rio de Janeiro, Brazil — For decades, South Africa has been at the epicentre of the global HIV epidemic. Today, it is becoming the testing ground for what many scientists believe could be the most important advance in HIV prevention since daily pre-exposure prophylaxis (PrEP): a twice-yearly injection that has shown almost complete protection against…
Cyberattacks, data breaches, online harassment and other forms of technology-facilitated violence are becoming significant obstacles to HIV prevention and treatment, according to a UNAIDS specialist who says digital security has become inseparable from the fight against the epidemic itself. As health and social services have moved online, protecting people’s privacy while making sure digital transformation…
Rio de Janeiro, Brazil — The global fight against HIV has never had more powerful scientific tools or faced greater political uncertainty. More than 7,000 scientists, activists, policymakers and community leaders gathered in Rio de Janeiro for the opening of the International AIDS Conference. Global leaders warned that decades of progress against the epidemic could be…
Rio de Janeiro, Brazil — The global HIV response stands at a defining moment, with health leaders warning that decades of progress are at risk as international funding declines and prevention programmes are scaled back across some of the world’s hardest-hit countries. Although new HIV infections and AIDS-related deaths have fallen to their lowest levels…
Rio de Janeiro, Brazil — HIV activists confronted U.S. officials before the official start of the AIDS 2026 conference over sweeping changes to Washington’s global HIV strategy, accusing the Trump administration of creating a public health emergency through funding cuts, while the United States defended a new financing model that it says will build more sustainable,…
Brazil has hosted clinical trials paving the way for lenacapavir’s approval and sale, but the medicine remains widely inaccessible for people there. As the 26th International AIDS Conference kicks off this weekend in Rio de Janeiro, Brazil, Doctors Without Borders/Médecins Sans Frontières (MSF) continues to urge the US pharmaceutical corporation Gilead Sciences to make the…
Twice-yearly injectable lenacapavir has continued to demonstrate exceptional protection against HIV infection. Twice-yearly injectable lenacapavir continued to provide strong protection against HIV in two landmark clinical trials, with updated data showing almost no new infections, high adherence and no new safety concerns. Researchers said updated findings from the PURPOSE-1 and PURPOSE-2 studies showed the long-acting…
